从此24年一直9月实现了年收入28.03亿元实现规模净利润1.71亿元三季度实现三季度实现收入8.72亿元同比降低了4.82个百分点三季度实现规模净利润4391万元同比降低了7.76%同时公司为了享有 政策号召加大了投资者合理汇报公司进行了中期分红每十股派发现金红利0.5元共派发了红利5082.84万元下面我将分个板块进行一个具体的一个简单介绍首先化妆品方面2024年19月公司化妆品板块实现营业收入17.08亿元红利增长了3.25 毛利率62.32%较去年同期少入提升其中伊莲品牌一直9月实现营业收入6.58亿元同比增长7.57%艾尔博士一直9月实现了营业收入9.09亿元同比增长1.80%研发软公司也加大了原料的储备利用合成生物学手段设备的网酱酸完成了化妆品新原料的编 提及了推进了医疗器械的注册工作取得了同名之专名叫医疗器械产品注册证公司二月医疗器械产品注册证增加值三项销售转一点品牌喷雾键创新文创IP点名销售2.0喷雾销售同比增长了21%喷润品线实现了支持了一元喷润面霜项目以面霜带动同系列喷润水乳销售 同一双销售同比增长54%软膜品线上新净膜新品达升了该品线的增量软膜销售同比增长22%二波式品牌闪充水乳升级销售 ...

鲁商福瑞达医药股份有限公司 2024 年第三季度业绩说明会会议纪要 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日（星期三）上午 10:00-11:00 通过上证路演中心网络文字互动方式，在上 海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/）召开了 公司 2024 年第三季度业绩说明会。 二、业绩说明会主要问题及回复情况 （一）预征集问题及回复 1、邮箱预征集问题回复 截止 2024 年 10 月 29 日 16：00，公司共征集到投资者问题 6 项，公司 对同类问题进行了整合，具体回复如下： （1）关于公司化妆品业务发货、产品开发、品牌建设等相关问题 现将召开情况汇总如下： 一、业绩说明会召开情况 公司董事长贾庆文先生，独立董事宿玉海先生，副总经理高春明先生，财 务总监许百强先生，副总经理、董事会秘书张红阳先生，出席了本次业绩说明 会。 本次业绩说明会由公司副总经理、董事会秘书张红阳主持，公司董事长贾 庆文发表了致辞。公司通过网络文字互动问答的形式就投资者关心的问题进行 了作答。投资者若需全面了解有关情况，可通过上海证券交易所上证 ...

证券代码：600223 证券简称：福瑞达 鲁商福瑞达医药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------|----------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | √其他电话会议 | | | | | 开源证券 华泰证券 国金证券 上海证券 海通证券 | | 参与单位名称及 | | 浙商证券 朱雀基金 国元证券 西部证券 民生证券 | | 人员姓名 | | 中泰证券 国泰君安 新华基金 东吴证券 中信建投 | | | | 德邦证券 广发证券 英大基金等 | | 时间 | 2024 年 10 月 | 31 日 15:00-16:00 | | 地点 | 线上会议 | | | 上市公司接待人 员姓名 | | 张红阳、白天明、姜良艳、徐世香、张泰生 | ...

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company has experienced a decline in revenue and net profit in the first three quarters of 2024, with revenue at 2.803 billion yuan, down 17.45% year-on-year, and net profit at 171 million yuan, down 28.09% year-on-year. However, the adjusted net profit increased by 40.09% year-on-year [2]. - The cosmetics business is under pressure, but the Yilian brand shows relative resilience, with revenue growth in the first three quarters of 2024 at 3.25% and a slight decline of 4.86% in Q3 [2]. - The pharmaceutical business has stabilized, with revenue in Q3 showing an 18.96% increase year-on-year, indicating a recovery in sales after price adjustments [2]. - The company is focusing on high-quality development across its pharmaceutical, cosmetics, and raw materials businesses, with expectations for improved profitability following the divestment of its real estate business [2]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 2.803 billion yuan, a decrease of 17.45% year-on-year, and a net profit of 171 million yuan, down 28.09% year-on-year. The adjusted net profit was 151 million yuan, up 40.09% year-on-year [2]. - In Q3 alone, revenue was 877 million yuan, down 4.82% year-on-year, and net profit was 44 million yuan, down 7.76% year-on-year [2]. Business Segments - The cosmetics segment generated revenue of 1.708 billion yuan in the first three quarters, with a slight increase of 3.25% year-on-year, while Q3 revenue was 522 million yuan, down 4.86% year-on-year. The Yilian brand showed resilience with a 7.57% increase in revenue for the first three quarters [2]. - The pharmaceutical segment reported revenue of 370 million yuan in the first three quarters, down 7.42% year-on-year, but Q3 saw an 18.96% increase, indicating a recovery [2]. - The raw materials and additives segment generated revenue of 249 million yuan in the first three quarters, down 1.96% year-on-year, with a 12% increase in sales of food-grade and cosmetic-grade hyaluronic acid [2]. Profitability and Cost Management - The company's gross margin for the first three quarters was 51.85%, an increase of 4.77 percentage points year-on-year. The net profit margin was 6.11%, down 0.90 percentage points year-on-year [2]. - The sales expense ratio was 36.47% for the first three quarters, up 4.43 percentage points year-on-year, while the management expense ratio decreased [2]. Future Outlook - The company is expected to achieve net profits of 291 million yuan in 2024, with a projected growth of 27.3% in 2025 and 21.8% in 2026. The corresponding PE ratios are forecasted to be 24, 19, and 15 for the respective years [3][5].

Investment Rating - The investment rating for the company is "Add" [5] Core Views - The company's revenue for the first three quarters of 2024 was 2.803 billion yuan, a year-on-year decline of 17.45%, primarily due to the previous year's revenue from the divested real estate business. The net profit attributable to the parent company was 171 million yuan, down 28.09% year-on-year, while the non-recurring net profit increased by 40.09% to 151 million yuan [1][2] - The gross margin increased by 4.77 percentage points to 51.85% due to the exclusion of low-margin real estate business from the previous year, while the net profit margin decreased by 1.41 percentage points to 7.48% [2] - The cosmetics segment generated revenue of 1.708 billion yuan in Q1-Q3 2024, with a year-on-year growth of 3.25%, while the pharmaceutical segment saw a revenue of 370 million yuan, down 7.42% year-on-year, but showed a recovery in Q3 with an 18.96% increase [3][4] Summary by Sections Financial Performance - For Q1-Q3 2024, the company reported a revenue of 2.803 billion yuan, a decrease of 17.45% year-on-year, and a net profit of 171 million yuan, down 28.09% year-on-year. The non-recurring net profit was 151 million yuan, up 40.09% [1] - The gross margin improved to 51.85%, while the net profit margin decreased to 7.48% [2] Business Segments - The cosmetics segment achieved revenue of 1.708 billion yuan, with a growth rate of 3.25%. The pharmaceutical segment's revenue was 370 million yuan, down 7.42%, but Q3 showed a recovery with an 18.96% increase [3] - The raw materials and additives segment reported revenue of 249 million yuan, a slight decline of 1.96%, but with a gross margin increase of 3.38 percentage points to 39.39% [3] Profit Forecast and Investment Recommendations - The company is focusing on the health industry, with a strategic upgrade in the cosmetics business. The earnings per share (EPS) forecast for 2024-2026 is adjusted to 0.28, 0.31, and 0.35 yuan per share, respectively [4][6] - The price-to-earnings (PE) ratio for 2024 is projected at 25 times, maintaining the "Add" rating [6]

Investment Rating - The report maintains a "Buy" rating for the company [5][10]. Core Insights - The company's Q3 revenue slightly declined, and profitability decreased, with a total revenue of 2.803 billion yuan for the first three quarters of 2024, down 17.45% year-on-year, and a net profit attributable to the parent company of 171 million yuan, down 28.09% year-on-year [3][4]. - The cosmetics segment is undergoing an adjustment phase, while the pharmaceutical segment shows signs of recovery, with pharmaceutical sales revenue in Q3 reaching 129 million yuan, up 18.96% year-on-year [4]. - The company is focusing on the health sector by divesting its real estate business and leveraging its strong R&D capabilities in cosmetics [5]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a gross margin of 51.81%, a decrease of 3.1 percentage points year-on-year, and a net profit margin of 6.08%, down 1.21 percentage points year-on-year [3]. - The cosmetics segment generated 1.708 billion yuan in revenue from January to September 2024, with a gross margin of 62.32% [4]. - The company expects EPS for 2024-2026 to be 0.28, 0.34, and 0.41 yuan, respectively, corresponding to P/E ratios of 25, 21, and 17 times [5]. Market Data - The company's market capitalization is approximately 7.045 billion yuan, with a circulating market value of 7.045 billion yuan [7]. - The stock price has fluctuated significantly over the past year, with a maximum price of 10.92 yuan and a minimum price of 5.89 yuan [7].

Investment Rating - The investment rating for the company is "Buy" and is maintained [2][5]. Core Views - The company reported a revenue of 2.8 billion yuan for the first three quarters of 2024, a year-on-year decrease of 17.45%, with a net profit attributable to the parent company of 171 million yuan, down 28.06% year-on-year [4][5]. - The cosmetics segment faced growth pressure, while the pharmaceutical segment showed a recovery with double-digit growth [5]. - The overall gross margin improved to 51.9%, up 4.8 percentage points year-on-year, despite a slight decline in net profit margin to 6.1% [5]. - The forecast for net profit attributable to the parent company for 2024 to 2026 is adjusted to 290 million yuan, 360 million yuan, and 430 million yuan, respectively, corresponding to P/E ratios of 26x, 21x, and 17x [5]. Company Overview - The total share capital is 1.017 billion shares, with a total market value of 7.5 billion yuan [3]. - The company has a debt-to-asset ratio of 40.1% and a P/E ratio of 24.50 [3]. - The largest shareholder is Shandong Commercial Group [3]. Financial Performance - For Q3 2024, the cosmetics segment generated 1.71 billion yuan in revenue, a year-on-year increase of 3.3%, while the pharmaceutical segment achieved 370 million yuan, a year-on-year decrease of 7.4% [5]. - The gross margins for cosmetics, pharmaceuticals, and raw materials were 62.3%, 50.5%, and 39.4%, respectively [5]. - The company’s sales expense ratio increased to 36.5%, while the management expense ratio decreased to 4.3% [5]. Earnings Forecast - The projected revenue for 2024 is 4.121 billion yuan, with a growth rate of -9.99% [6]. - The expected net profit for 2024 is 291 million yuan, reflecting a decrease of 4.02% [6]. - The earnings per share (EPS) for 2024 is estimated at 0.29 yuan [6].

Investment Rating - The report maintains a "Buy" rating for the company [1][6][10] Core Views - The company reported a revenue of 2.803 billion yuan for the first three quarters of 2024, a year-on-year decrease of 17.45%, and a net profit attributable to shareholders of 171 million yuan, down 28.09% year-on-year, primarily due to the impact of the divestment of its real estate business [3][4][6] - The company has shown a significant increase in non-recurring net profit, which reached 151 million yuan, reflecting a 40.09% year-on-year growth, attributed to improved cost control and the effects of the real estate divestment [3][6] - The report anticipates a recovery in performance, projecting net profits for 2024-2026 to be 357 million, 486 million, and 548 million yuan respectively, with corresponding price-to-earnings ratios of 21, 15, and 14 times [6][10] Financial Performance Summary - For the first three quarters of 2024, the gross margin was 51.85%, an increase of 4.77 percentage points year-on-year, while the net profit margin was 6.11%, a decrease of 0.90 percentage points year-on-year [4][6] - The cosmetics segment generated revenue of 1.708 billion yuan, a year-on-year increase of 3.25%, with a gross margin of 62.32% [5][6] - The pharmaceutical segment reported revenue of 370 million yuan, a year-on-year decrease of 7.42%, with a gross margin of 50.48% [5][6] - The raw materials and derivatives segment saw revenue of 249 million yuan, down 1.96% year-on-year, with a gross margin of 39.39% [5][6] Research and Development - The company has strengthened its raw material reserves and upgraded its product lines, leading to increased sales in several categories, including a 21% year-on-year increase in sales of the Yilian spray line [6][10] - The company aims to build a comprehensive health industry chain, advancing in cosmetics, raw materials, and pharmaceuticals [6][10]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's Q3 2024 performance shows short-term pressure on earnings, but the launch of upgraded products is expected to drive future growth [2][5] - The company is focusing on the health industry and is gradually improving efficiency through organizational adjustments and strategic focus [5] Summary by Relevant Sections Financial Performance - For the first three quarters of 2024, the company reported revenue of 2.803 billion yuan, a decrease of 17.45% year-on-year, and a net profit attributable to shareholders of 171 million yuan, down 28.09% [2] - Q3 2024 revenue was 877 million yuan, a decline of 4.82%, with a net profit of 44 million yuan, down 7.76% [2] Cosmetics Segment - The cosmetics revenue for the first three quarters of 2024 was 1.708 billion yuan, an increase of 3.25% year-on-year [3] - The Yilian brand generated 658 million yuan in revenue, growing by 7.57%, although Q3 showed some volatility [3] - New product iterations performed well, with sales of the 2.0 spray increasing by 21% and the "Pongrun" product line seeing a 54% increase in cream sales [3] Pharmaceutical and Raw Materials - Pharmaceutical and raw material revenues for the first three quarters were 370 million yuan and 250 million yuan, respectively, with year-on-year declines of 7.4% and 2.0% [4] - Q3 revenues for pharmaceuticals and raw materials were 130 million yuan and 80 million yuan, showing increases of 18.7% and declines of 7.5% year-on-year, respectively [4] Cost Management - The gross margin for the first three quarters of 2024 increased by 4.77 percentage points to 51.85% [5] - The net profit margin for the first three quarters was 6.11%, a decrease of 0.9 percentage points year-on-year [5] Earnings Forecast - The forecast for net profit attributable to shareholders for 2024-2026 has been adjusted to 290 million, 390 million, and 480 million yuan, respectively, with corresponding P/E ratios of 26, 19, and 16 times [5]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [4] Core Views - The company is in a transformation phase, focusing on strengthening its internal capabilities and is optimistic about the upcoming Double 11 sales performance [8] - The cosmetics segment is under pressure during the off-season, while the pharmaceutical segment has stabilized in Q3 [7] - The company has made significant progress in product innovation and brand development, particularly in the cosmetics sector [8] Financial Performance Summary - For the first three quarters of 2024, the company's total revenue was 2.803 billion yuan, a year-on-year decrease of 17.4%, with a net profit attributable to shareholders of 171 million yuan, down 28.1% [6] - In Q3 2024, revenue was 877 million yuan, a year-on-year decrease of 4.8%, and net profit attributable to shareholders was 44 million yuan, down 7.8% [6] - The cosmetics segment generated revenue of 1.708 billion yuan, up 3.25% year-on-year, while the pharmaceutical segment's revenue was 370 million yuan, down 7.42% year-on-year [7] Business Segment Analysis - The cosmetics segment showed resilience with brands like Yilian and Aier Bozhu achieving year-on-year revenue growth of 7.57% and 1.80% respectively [7] - The pharmaceutical segment's sales stabilized with an 18.96% year-on-year increase in Q3 [7] - The raw materials and additives segment reported revenue of 249 million yuan, down 1.96% year-on-year [7] Strategic Initiatives - The company is enhancing its raw material reserves and has completed the registration of new cosmetic ingredients using synthetic biology [8] - Innovative marketing strategies, such as collaborations for product launches, have led to significant sales growth in various product lines [8] - The company is expanding into collagen and hair care markets, with new product launches receiving positive market feedback [8] Future Projections - Revenue projections for 2024-2026 are 4.008 billion yuan, 4.590 billion yuan, and 5.170 billion yuan, with corresponding growth rates of -12.5%, 14.5%, and 12.6% [8] - Net profit projections for the same period are 271 million yuan, 321 million yuan, and 370 million yuan, with growth rates of -10.6%, 18.2%, and 15.5% respectively [8] - Earnings per share (EPS) are expected to be 0.27 yuan, 0.32 yuan, and 0.36 yuan for 2024-2026 [8]